Skip to main content

SLS SELLAS Life Sciences Group, Inc.

Healthcare

8.87 USD 1D +0.32 +3.74% Close 11/3
Since 2024-12-03 +624.6%
Open
8.70
High
9.18
Low
8.58
Prev close
8.55
Volume
5M
Amplitude
7.02%
P/B
12.5
Revenue YoY (TTM)
-100.0%
52W 1.39 15.88

Is SELLAS Life Sciences Group, Inc. a buy? Fundamentals and valuation first

As of 2026-11-02

Momentum: Good; Valuation: Pricey, Growth: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -40.46 N/A
Price / book 12.54 94th percentile Expensive
Free-cash-flow yield (%) -1.65 39th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral ROE, TTM is Average.
ROE, TTM (%) -23.58 24th percentile Average
Operating margin, TTM (%) — N/A
FCF margin, TTM (%) — N/A
Quality Factor Investing: A US Quality Value Backtest
Growth Weak Diluted EPS growth, TTM YoY is Average; Revenue growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) -100 3th percentile Lagging
Diluted EPS growth, TTM YoY (%) -35.44 40th percentile Average
Momentum Good 240-day return is Top, but 60-day return is Average.
60-day return (%) -28.81 20th percentile Average
240-day return (%) 506.38 100th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Lagging.
20-day dollar volume 77,545,008 85th percentile Top
60-day annualized volatility (%) 97.34 82th percentile Lagging
Factor Investing Explained: 10 Classic Factors in US Stocks

SELLAS Life Sciences Group, Inc. (SLS) today

1 quant signals active · As of 2026-11-02

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From SELLAS Life Sciences Group, Inc. to every stock like it

AI finds several complementary traits of SELLAS Life Sciences Group, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. (SLS) peers and tracking

Watchlist

This page refreshes daily after the close. Add SELLAS Life Sciences Group, Inc. to your watchlist to track signal changes on your next visit.

SELLAS Life Sciences Group, Inc. (SLS) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 95.66%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
19 historical occurrences (since 2019-01-24)

Average forward return after Top-quintile 6-month momentum

20-day: Win 31.6%, Sample 19, Median -5.19%, Excess -8.29%, Beat mkt rate 31.6%

60-day: Win 31.6%, Sample 19, Median -13.97%, Excess -9.24%, Beat mkt rate 31.6%

120-day: Win 36.8%, Sample 19, Median -13.24%, Excess +8.53%, Beat mkt rate 36.8%

120 days after: historical avg +18.4%

20-day -5.13%
60-day -4.33%
120-day +18.4%
20-day
60-day
120-day
Win
31.6%
31.6%
36.8%
Sample
19
19
19
Median
-5.19%
-13.97%
-13.24%
Excess
-8.29%
-9.24%
+8.53%
Beat mkt rate
31.6%
31.6%
36.8%

Over 19 occurrences, 120-day forward avg gained 18.4%, beat the market by 8.53 pts; win rate 36.8%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,771 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.43%, a 58.5% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 times historically; 60-day forward avg +43.59%, win rate 71.4%, beating the market by +37.32 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

22 times historically; 60-day forward avg +11.38%, win rate 50%, beating the market by +6.62 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.